Optimal dilution of the Ki-67 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. FACS: 1-2 μg/10^6 cells in 0.1ml,IF/ICC: 1-2 μg/mL,IHC (FFPE): 1-2 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)
限制
仅限研究用
缓冲液
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
储存液
Sodium azide
注意事项
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
4 °C,-20 °C
储存方法
Store the Ki-67 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
抗原
Ki-67 (MKI67)
(Antigen Identified By Monoclonal Antibody Ki-67 (MKI67))
别名
Ki67
背景
Ki67 antigen is a nuclear, non-histone protein that is present in all stages of the cell cycle except G0. This characteristic makes Ki67 an excellent marker for proliferating cells and is commonly used as one of the prognostic factors in cancer studies. A correlation has been demonstrated between Ki67 index and the histo-pathological grade of neoplasms. Assessment of Ki67 expression in renal and ureter tumors shows a correlation between tumor proliferation and disease progression, thus making it possible to differentiate high-risk patients. Ki-67 expression may also prove to be important for distinguishing between malignant and benign peripheral nerve sheath tumors. Ki67 labeling index has been shown to be a prognostic marker in a number of neoplasms including grade II astrocytoma, oligodendroglioma, colon carcinoma, and breast carcinoma. In general, Ki67 is a good marker of proliferating cell populations.